The National Day for Truth and Reconciliation on September 30th has been incorporated into the Federal Courts Rules definition of “holiday”. The Federal Court issued a notice reminding litigants to take this holiday into account when computing deadlines and that hearings are being rescheduled.
Several IP related amendments have been published in the Canada Gazette:
- College-related for the coming into force of the College on June 28th (see earlier post):
- By-laws of the College of Patent Agents and Trademark Agents (Board),
- By-laws of the College of Patent Agents and Trademark Agents (College),
- Code of Professional Conduct for Patent Agents and Trademark Agents Regulations,
- Order Fixing the Number of Directors Under the College of Patent Agents and Trademark Agents Act
- Amendments to the Federal Courts Rules that came into force on June 17th (see earlier post):
- PMPRB-related (see earlier post on delaying Patented Medicines Reporting Requirements that were to come into force on July 1st): Regulations amending the Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements)
Proposed amendments to the Patent Rules are published for consultation in the Canada Gazette to address patent term adjustment and other changes to streamline prosecution. The proposed amendments include excess claim fees, limits on office actions and requests for continued examination, updating rules on sequence listings and some miscellaneous amendments.
There are reports that the government has again delayed the coming-into-force of the substantive changes to the Patented Medicines Prices Review Board guildelines by six-months. The updates had been scheduled to come into force on July 1st. Continue reading PMPRB
Amendments to the Federal Courts Rules have been registered based on proposed amendments published back in 2016. These amendments include (1) increases to the monetary limit for prothonotaries and for simplified actions; (2) provide for excerpts in books of authorities; (3) a timeline for filing of books of authorities in appeals; (4) condensed appeal books; (5) establishing a “Notice of Intention to Respond” and standardize the timeline for filing a defence for defendants who are served in either Canada or the United States; and (6) clarifying the material to be contained in an applicant’s record.
The various amendments relating to the Patented Medicines Prices Review Board mentioned in my update earlier this week have now been published in the Canada Gazette Part 2.
Various amendments relating to the Patented Medicines Prices Review Board are to come into force on June 30, 2021 including amendments to sections 79 to 103 of the Patent Act. In addition there are some changes being made for consistency with the Patent Act and to encompass CSPs. This is in addition to the amended Patented Medicines Regulations expanding reporting requirements are scheduled to come into force July 1, 2021 after being delayed several times. Continue reading PMPRB
The Federal Court of Appeal, in a new Practice Notice “Electronic Service of Documents for the duration of the Suspension Period”, makes electronic service by email permissible in all cases and requires email addresses be added to all documents filed with the Federal Court of Appeal, with limited exceptions, while the, now indefinite, Suspension Period is in effect.
The Federal Court has published revised consolidated intellectual property guidance for case management and trial management. The Court has included a blackline version which indicates that changes include limiting “second round” discovery, use of claim charts, compendia and slide decks at trial and requests to admit.
Proposed amendments to the Patented Medicines (Notice of Compliance) Regulations have been published for consultation in the Canada Gazette to expand the definition of a “claim for medicinial ingredient” to include salts so that “the scope of protection under the Regulations corresponds to the type of activities contemplated under the proposed amendments to the [Food and Drug Regulations]”. Continue reading PM(NOC)